In a phase I study that included 51 adult patients with ALL,1 the CR rate with JCAR015 was 77% in those with morphologic disease (n = 31) and 90% in those with minimal disease (n = 20). At the time of the analysis, the median overall survival (OS) was not yet reached for those in the minimal disease arm. The median OS was 9 months for those with morphologic disease.
"We remain encourage by the ability of JCAR015 to treat ALL," said Hans Bishop, CEO at Juno Therapeutics. "The [ASCO] results show a marked improvement over traditional cytotoxic chemotherapy for adult ALL patients."
17:12 Neymar loses appeal, will stand trial on corruption charges for Barcelona move11
09:32 In Europe, Pence says US will hold Russia accountable25
19:08 Low vitamin D levels linked to relapse of ulcerative colitis21
10:01 Campaign Over, President Trump Will Hold a (What Else?) Campaign Rally22